257 related articles for article (PubMed ID: 16083971)
1. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate.
Azoulay D; Vachapova V; Shihman B; Miler A; Karni A
J Neuroimmunol; 2005 Oct; 167(1-2):215-8. PubMed ID: 16083971
[TBL] [Abstract][Full Text] [Related]
2. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-beta 1a, and high doses of immunoglobulins.
Sarchielli P; Zaffaroni M; Floridi A; Greco L; Candeliere A; Mattioni A; Tenaglia S; Di Filippo M; Calabresi P
Mult Scler; 2007 Apr; 13(3):313-31. PubMed ID: 17439900
[TBL] [Abstract][Full Text] [Related]
3. A longitudinal observation of brain-derived neurotrophic factor mRNA levels in patients with relapsing-remitting multiple sclerosis.
Liguori M; Fera F; Patitucci A; Manna I; Condino F; Valentino P; Telarico P; Cerasa A; Gioia MC; di Palma G; Quattrone A
Brain Res; 2009 Feb; 1256():123-8. PubMed ID: 19071096
[TBL] [Abstract][Full Text] [Related]
4. Effect of glatiramer acetate on peripheral blood brain-derived neurotrophic factor and phosphorylated TrkB levels in relapsing-remitting multiple sclerosis.
Vacaras V; Major ZZ; Muresanu DF; Krausz TL; Marginean I; Buzoianu DA
CNS Neurol Disord Drug Targets; 2014; 13(4):647-51. PubMed ID: 24938775
[TBL] [Abstract][Full Text] [Related]
5. [Glatiramer acetate in interferon beta non respondent relapsing-remitting multiple sclerosis].
Oreja-Guevara C; Bermejo PE; Miralles A; Gabaldón L; Aguilar MJ; Díez-Tejedor E
Neurologia; 2009 Sep; 24(7):435-8. PubMed ID: 19921551
[TBL] [Abstract][Full Text] [Related]
6. Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis.
Valenzuela RM; Costello K; Chen M; Said A; Johnson KP; Dhib-Jalbut S
Mult Scler; 2007 Jul; 13(6):754-62. PubMed ID: 17613604
[TBL] [Abstract][Full Text] [Related]
7. Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases.
Ball NJ; Cowan BJ; Moore GR; Hashimoto SA
J Cutan Pathol; 2008 Apr; 35(4):407-10. PubMed ID: 18333902
[TBL] [Abstract][Full Text] [Related]
8. Investigating the role of brain-derived neurotrophic factor in relapsing-remitting multiple sclerosis.
Liguori M; Fera F; Gioia MC; Valentino P; Manna I; Condino F; Cerasa A; La Russa A; Clodomiro A; Paolillo A; Nisticò R; Vercillo L; Cittadella R; Quattrone A
Genes Brain Behav; 2007 Mar; 6(2):177-83. PubMed ID: 16740142
[TBL] [Abstract][Full Text] [Related]
9. Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy.
Caggiula M; Batocchi AP; Frisullo G; Angelucci F; Patanella AK; Sancricca C; Nociti V; Tonali PA; Mirabella M
Clin Immunol; 2006 Jan; 118(1):77-82. PubMed ID: 16275091
[TBL] [Abstract][Full Text] [Related]
10. Altered serum content of brain-derived neurotrophic factor isoforms in multiple sclerosis.
Tongiorgi E; Sartori A; Baj G; Bratina A; Di Cola F; Zorzon M; Pizzolato G
J Neurol Sci; 2012 Sep; 320(1-2):161-5. PubMed ID: 22836016
[TBL] [Abstract][Full Text] [Related]
11. Blocking effects of serum reactive antibodies induced by glatiramer acetate treatment in multiple sclerosis.
Salama HH; Hong J; Zang YC; El-Mongui A; Zhang J
Brain; 2003 Dec; 126(Pt 12):2638-47. PubMed ID: 12937077
[TBL] [Abstract][Full Text] [Related]
12. Interferon-beta induces brain-derived neurotrophic factor in peripheral blood mononuclear cells of multiple sclerosis patients.
Lalive PH; Kantengwa S; Benkhoucha M; Juillard C; Chofflon M
J Neuroimmunol; 2008 Jul; 197(2):147-51. PubMed ID: 18555540
[TBL] [Abstract][Full Text] [Related]
13. Bystander modulation of chemokine receptor expression on peripheral blood T lymphocytes mediated by glatiramer therapy.
Allie R; Hu L; Mullen KM; Dhib-Jalbut S; Calabresi PA
Arch Neurol; 2005 Jun; 62(6):889-94. PubMed ID: 15956159
[TBL] [Abstract][Full Text] [Related]
14. Glatiramer acetate could be a potential therapeutic agent for Parkinson's disease through its neuroprotective and anti-inflammatory effects.
Tsai SJ
Med Hypotheses; 2007; 69(6):1219-21. PubMed ID: 17548170
[TBL] [Abstract][Full Text] [Related]
15. Glatiramer acetate: mechanisms of action in multiple sclerosis.
Ziemssen T; Schrempf W
Int Rev Neurobiol; 2007; 79():537-70. PubMed ID: 17531858
[TBL] [Abstract][Full Text] [Related]
16. Phase III dose-comparison study of glatiramer acetate for multiple sclerosis.
Comi G; Cohen JA; Arnold DL; Wynn D; Filippi M;
Ann Neurol; 2011 Jan; 69(1):75-82. PubMed ID: 21280077
[TBL] [Abstract][Full Text] [Related]
17. Glatiramer acetate-specific human CD8(+) T cells: increased IL-4 production in multiple sclerosis is reduced by glatiramer acetate treatment.
Dressel A; Vogelgesang A; Brinkmeier H; Mäder M; Weber F
J Neuroimmunol; 2006 Dec; 181(1-2):133-40. PubMed ID: 17084909
[TBL] [Abstract][Full Text] [Related]
18. Glatiramer acetate treatment of multiple sclerosis: an immunological perspective.
Racke MK; Lovett-Racke AE
J Immunol; 2011 Feb; 186(4):1887-90. PubMed ID: 21289312
[TBL] [Abstract][Full Text] [Related]
19. Anti-depressant use in association with interferon and glatiramer acetate treatment in multiple sclerosis.
Patten SB; Williams JV; Metz LM
Mult Scler; 2008 Apr; 14(3):406-11. PubMed ID: 17986504
[TBL] [Abstract][Full Text] [Related]
20. Sporadic CJD in a patient with relaplsing-remitting multiple sclerosis on an immunomodulatory treatment.
Gabelić T; Habek M; Zerr I; Gawinecka J; Pavlisa G; Brinar VV
Acta Neurol Belg; 2011 Sep; 111(3):232-6. PubMed ID: 22141291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
